Despite $2B AML Deal, AbbVie Stops Early Cancer Combo Trial With I-Mab
I-Mab quietly announced that its partner AbbVie is ending a Phase IB trial on lemzoparlimab for two types of cancers, despite a $2 billion deal inked in 2020.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Positive Data Back Blueprint’s Bid for sNDA in Systemic Mastocytosis
/in TherapeuticsBlueprint Medicines’ Ayvakit (avapritinib) is headed to the FDA for a new indication after the drug hit the mark in Part 2 of the PIONEER trial for non-advanced systemic mastocytosis.
Investors Continue to Fund Data Over Ideas In Current Biotech Downturn
/in TherapeuticsThe United States is in the early days of a recession and the biotech industry is in a bit of a slump. CEOs can take heart, however, by applying the lessons of previous recessions to business today and understanding what is different about the current situation.
Sanofi trial failure halts work on breast cancer treatment amcenestrant
/in TherapeuticsAlthough the treatment was once seen to have strong commercial potential in breast cancer, this second trial failure deals a major blow to the French healthcare company’s development prospects.
Quest Diagnostics Aims to Close Gaps in Maternal Healthcare with New Obstetrics Test Panel that Includes Hepatitis C Screening
/in TherapeuticsThe new test panel follows a Quest Diagnostics Health Trends study with the CDC that revealed less than half of pregnant people are screened for hepatitis C as recommended under guidelines.
Plaintiff in first Zantac lawsuit set for trial drops case
/in Marketing & Advertising, TherapeuticsThe news came days after shares of GlaxoSmithKline Plc, Sanofi SA, Pfizer Inc, and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer.
Endo files for bankruptcy as U.S. opioid litigation drags
/in Issue Archives, Marketing & AdvertisingEndo International Plc filed for bankruptcy on Tuesday after reaching a $6 billion deal with some of its creditors, as the U.S. drugmaker seeks to settle thousands of lawsuits over its alleged role in the country’s opioid epidemic.
U.S. FDA gets over 48,000 reports of faulty Philips respiratory devices in May-July
/in Marketing & AdvertisingThe agency said it received more than 48,000 reports of faulty Dutch medical equipment maker Philips’ ventilators and respiratory devices between May and July of this year.
Gilead’s Trodelvy gives Enhertu a run for its money in metastatic breast cancer
/in R&D, TherapeuticsWeeks after AstraZeneca and Daiichi Sankyo were able to move the bar in the treatment of metastatic breast cancer with Enhertu, Gilead Sciences is answering that challenge with Trodelvy.
Merck makes another big R&D investment with $3.5B Orna deal
/in R&D, TherapeuticsOn a collaboration streak, Merck is pouring a potential $3.5 billion into a partnership with circular RNA company Orna Therapeutics to develop and commercialize multiple oncology and infectious disease programs.